Cargando…
THU510 The Frequency Of Mutations In Advanced Thyroid Cancer In Japan: A Real Clinical Setting
Disclosure: S. Toda: None. A. Takahashi: None. K. Masudo: None. H. Iwasaki: None. Background: Thyroid cancer has a high incidence of actionable genetic alterations, but the frequency of mutations in advanced thyroid cancer that requires drug therapy is unknown. Therefore, we examined the outcomes of...
Autores principales: | Toda, Soji, Takahashi, Akari, Masudo, Katsuhiko, Iwasaki, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553623/ http://dx.doi.org/10.1210/jendso/bvad114.2138 |
Ejemplares similares
-
Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2023) -
Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
por: Toda, Soji, et al.
Publicado: (2021) -
Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020) -
THU484 Distinct Genetic Characteristics In Follicular Thyroid Cancer With Different Metastatic Potentials
por: Kwak, Soo-jung, et al.
Publicado: (2023) -
THU535 Anti-angiogenic Multi-kinase Inhibitor In NUTM1 Rearranged Carcinoma Of Thyroid
por: Tella, Sri Harsha, et al.
Publicado: (2023)